Randomized trial uncovers RUNX1 alterations linked to poor prognosis in pediatric AML-M0, suggesting new treatment strategies.
Key Points
This research aims to uncover the molecular characteristics and treatment challenges of pediatric minimally differentiated acute myeloid leukemia (AML-M0).
Conducted a multi-omics analysis of 23 pediatric AML-M0 cases compared to 1483 leukemia samples.
Performed functional analyses utilizing CRISPR/Cas9 to knockout RUNX1 in a pediatric AML-M0 cell line.
Examined genomic alterations, DNA hypermethylation, and gene expression related to chemotherapy resistance.
Identified RUNX1 alterations in 26% of cases, significantly associated with poor prognosis.
RUNX1 disruption led to decreased sensitivity to drugs such as cytarabine and anthracyclines.
AML-M0 samples exhibited global DNA hypermethylation and transcriptional suppression compared to non-M0 AML.